Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 462390019 | Propranolol hydrochloride+bendrofluazide 80mg/2.5mg capsule | en | Synonym (core metadata concept) | Inactive | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 714784011 | Propranolol hydrochloride+bendrofluazide 80mg/2.5mg capsule (substance) | en | Fully specified name | Inactive | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 1188445015 | Propranolol hydrochloride+bendrofluazide 80mg/2.5mg capsule (product) | en | Fully specified name | Inactive | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 2153206016 | Propranolol hydrochloride 80mg / bendrofluazide 2.5mg capsule (product) | en | Fully specified name | Inactive | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 2160837011 | Propranolol hydrochloride 80mg / bendrofluazide 2.5mg capsule | en | Synonym (core metadata concept) | Inactive | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 3470754013 | Propranolol hydrochloride 80 mg and bendroflumethiazide 2.5 mg/1 each oral capsule | en | Synonym (core metadata concept) | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3470755014 | Product containing propranolol hydrochloride 80 mg and bendroflumethiazide 2.5 mg/1 each oral capsule | en | Synonym (core metadata concept) | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3483407018 | Product containing propranolol hydrochloride 80 mg and bendroflumethiazide 2.5 mg/1 each oral capsule (clinical drug) | en | Fully specified name | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3565288012 | Product containing only propranolol hydrochloride 80 mg and bendroflumethiazide 2.5 mg/1 each oral capsule | en | Synonym (core metadata concept) | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3565289016 | Product containing only propranolol hydrochloride 80 mg and bendroflumethiazide 2.5 mg/1 each oral capsule (clinical drug) | en | Fully specified name | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3682423017 | Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3682424011 | Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule | en | Synonym (core metadata concept) | Inactive | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3682425012 | Bendroflumethiazide 2.5 mg and propranolol hydrochloride 80 mg oral capsule | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3379431000005119 | propranololhydrochlorid 80 mg/bendrofluazid 2,5 mg kapsel | da | Synonym (core metadata concept) | Inactive | Entire term case insensitive (core metadata concept) | Danish module (core metadata concept) |
| 4714471000005110 | propranololhydrochlorid 80 mg + bendrofluazid 2,5 mg kapsel | da | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | Danish module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Is a | propranolol + diuretikum | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Diuretic (substance) | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Propranolol (substance) | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Is a | Propranolol hydrochloride + bendrofluazide | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Bendroflumethiazide (substance) | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Bendrofluazide - chemical | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Propranolol hydrochloride | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Has manufactured dose form | A solid single-dose form that is a shell made of gelatin or other substances. The contents of the shell may be a solid, semi-solid or liquid. | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Is a | Product containing bendroflumethiazide and propranolol (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Has manufactured dose form | Oral capsule | true | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Is a | Propranolol-containing product in oral dose form | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Bendroflumethiazide (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Bendroflumethiazide (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength numerator value | 2.5 | false | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength denominator value | en | false | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Capsule (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Propranolol hydrochloride | false | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Propranolol hydrochloride | true | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength numerator value | 80 | false | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength denominator value | en | false | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Capsule (unit of presentation) | true | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Propranolol hydrochloride | false | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength numerator value | 80 | false | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Bendroflumethiazide (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Has presentation strength numerator value | 2.5 | false | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Is a | Bendroflumethiazide-containing product in oral dose form | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Has unit of presentation | Capsule (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Bendroflumethiazide (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Propranolol hydrochloride | false | Inferred relationship | Some | 1 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Count of base of active ingredient | to | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Is a | Bendroflumethiazide and propranolol only product in oral dose form | true | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | Plays role | Diuretic therapeutic role | false | Inferred relationship | Some | ||
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Propranolol hydrochloride | true | Inferred relationship | Some | 2 | |
| Product containing precisely bendroflumethiazide 2.5 milligram and propranolol hydrochloride 80 milligram/1 each conventional release oral capsule (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Bendroflumethiazide (substance) | true | Inferred relationship | Some | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR